Darunavir Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Darunavir Supply and Access in 2026

As an HIV care provider, you know that medication adherence is the single most important factor in long-term viral suppression. When patients report difficulty filling their Darunavir prescriptions, it's critical to understand whether the issue is a genuine supply shortage, a pharmacy stocking gap, or an insurance barrier — because the solution is different for each.

This briefing summarizes the current Darunavir supply landscape, prescribing implications, cost considerations, and tools you can use to help patients maintain uninterrupted access to their antiretroviral therapy.

Current Supply Status

As of early 2026, Darunavir is not on the FDA Drug Shortage Database. Neither brand-name Prezista nor generic Darunavir formulations are experiencing documented supply disruptions.

Since the first generic approval in September 2022 (Lupin Ltd.), multiple ANDA holders have entered the market, including Mylan, Teva, Cipla, Aurobindo, Dr. Reddy's, Hetero Labs, MSN, Amneal, Annora Pharma, and Zydus Lifesciences. This broad generic base provides substantial supply redundancy.

The combination products Prezcobix (darunavir/cobicistat) and Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) remain brand-only and are manufactured by Janssen Products, LP.

Timeline: Key Milestones

• June 2006: FDA approves Darunavir (Prezista) for treatment-experienced adults
• October 2008: Expanded approval for treatment-naive adults
• 2012: Pediatric approval for patients ≥3 years
• January 2015: Prezcobix (darunavir/cobicistat) approved
• July 2018: Symtuza approved as complete single-tablet regimen
• September 2022: First generic Darunavir approved (Lupin Ltd.)
• 2022-2024: Multiple additional generic manufacturers receive FDA approval
• 2026: No active shortage; stable multi-manufacturer generic supply

Prescribing Implications

When Patients Report Difficulty Filling

In most cases, patient-reported difficulty is due to:

1. Pharmacy stocking gaps: Chain pharmacies may not routinely stock Darunavir. Solution: direct patients to specialty pharmacies or use Medfinder for Providers to identify pharmacies with current stock.
2. Prior authorization delays: Particularly for brand-name Prezista, Prezcobix, or Symtuza. Consider prescribing generic Darunavir + generic Ritonavir when clinically appropriate to reduce PA requirements.
3. Formulary restrictions: Some payers place Darunavir on specialty tiers or behind step-therapy requirements favoring INSTIs. Peer-to-peer review may be needed to override.

Generic Prescribing Considerations

Generic Darunavir is available in 400 mg, 600 mg, and 800 mg tablets. When prescribing generically:

• Write "darunavir" (not Prezista) to allow generic dispensing
• Ensure the prescription includes the required booster (ritonavir or cobicistat)
• Note that the oral suspension remains brand-only (Prezista 100 mg/mL) — relevant for pediatric patients
• Generic bioequivalence has been established; therapeutic substitution is appropriate

Combination Products

For patients on complex multi-tablet regimens, consider:

• Prezcobix (DRV 800 mg/COBI 150 mg): Reduces pill count by combining PI + booster
• Symtuza (DRV/c/FTC/TAF): Complete STR for eligible patients, simplifying adherence

Both remain brand-only with higher costs but may improve adherence, which directly impacts viral suppression and transmission risk.

Cost and Access Landscape

Cost remains a significant barrier for some patients:

• Brand Prezista (800 mg, 30 tabs): ~$1,300-$2,500/month
• Generic Darunavir (800 mg, 30 tabs): ~$400-$800 retail; $60-$150 with discount coupons
• Prezcobix: ~$2,000-$3,000/month (brand only)
• Symtuza: ~$3,500-$4,500/month (brand only)

Coverage and Assistance Programs

• ADAP (AIDS Drug Assistance Programs): Available in all 50 states for qualifying patients; covers Darunavir
• Ryan White HIV/AIDS Program: Covers medications through funded clinics and pharmacies
• J&J withMe Savings Program: Reduces copay to as low as $0 for commercially insured patients on Prezista, Prezcobix, or Symtuza
• Johnson & Johnson Patient Assistance Foundation (JJPAF): Provides free Prezista to uninsured/underinsured patients for up to 1 year
• 340B Program: Covered entities can purchase Darunavir at significantly reduced prices
• Discount cards: GoodRx ($69+), SingleCare ($63+) for generic

For a detailed patient-facing resource on savings, refer patients to our Darunavir savings guide.

Tools and Resources for Providers

• Medfinder for Providers: Real-time pharmacy stock checking tool. Help patients find Darunavir at pharmacies near them before they leave your office.
• JJPAF Patient Assistance: 1-800-652-6227 or prezista.com
• FDA Drug Shortage Database: fda.gov/drugs/drug-shortages
• ADAP Directory: Contact your state health department for local ADAP enrollment
• HIV Treatment Guidelines: clinicalinfo.hiv.gov for current DHHS recommendations

Looking Ahead

The Darunavir supply outlook for 2026 and beyond is generally positive:

• Broad generic manufacturer base reduces risk of supply disruptions
• Ongoing ANDA approvals continue to increase competition and lower costs
• Combination products (Prezcobix, Symtuza) remain brand-only, presenting higher cost but strong adherence benefits
• Evolving treatment guidelines increasingly favor INSTI-based regimens as first-line, but boosted PI regimens remain essential for treatment-experienced patients, those with INSTI resistance, and specific clinical scenarios

Providers should monitor the FDA drug shortage database and maintain relationships with specialty pharmacies that can reliably supply antiretroviral medications. For a complementary resource on helping patients access Darunavir, see our provider's guide to helping patients find Darunavir.

Final Thoughts

Darunavir remains a critical component of HIV treatment, particularly for treatment-experienced patients and those requiring PI-based regimens. While no formal shortage exists, practical barriers — pharmacy stocking, insurance requirements, and cost — continue to challenge patient access.

By prescribing generically when appropriate, connecting patients with assistance programs, and using tools like Medfinder for Providers, clinicians can play an active role in ensuring their patients maintain uninterrupted access to this essential medication.